Cardiosense is building a physiological waveform AI platform to develop predictive biomarkers to detect and manage cardiovascular disease. The Company has developed a suite of novel digital tools, multi-sensor devices, and analysis algorithms to detect changes in cardiovascular disease non-invasively, inform personalized therapy, and improve patient outcomes. The Company is currently pursuing clinical development of its clinical-grade, multi-parameter, non-invasive monitoring device, CardioTag, with an initial focus on improving the monitoring and management of patients with congestive heart failure (CHF).
Go to website: https://cardiosense.com